Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis

Autoimmune Encephalitis Clinical Trial

— NMDARE-HSE  

Official title:

Study of 12 Cases of Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis and Review of the Literature

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04339127
• Other study ID #: NMDARE-HSE
• Status: Recruiting
• Start date: April 1, 2020
• Est. completion date: October 1, 2020

Study information

• Verified date: April 2020
• Source: Hospices Civils de Lyon
• Contact: Jérôme Honnorat, PhD
• Phone: 04 72 35 78 06
• Email: jerome.honnorat[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate.

One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis.

The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: October 1, 2020
• Est. primary completion date: June 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in the CSF

• After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF

• Without age limit

Exclusion Criteria- No respect of inclusion criteria

Related Conditions & MeSH terms

• Anti NMDA Receptor Encephalitis
• Anti-N-Methyl-D-Aspartate Receptor Encephalitis
• Autoimmune Encephalitis
• Encephalitis
• Hashimoto Disease
• Herpetic Encephalitis

Intervention

Other:
• Description and analysis
Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.

Locations

Country	Name	City	State
France	Hospice Civils de Lyon	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Details of clinical, biological, imaging, therapeutic characteristics and patient's evolution.	Retrospective collection of clinical, diagnostic and therapeutic data, evolution at 6 and 12 months.	at 6 and 12 months